Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.
Revenue Compound Annual Growth Rate in the last 5 years.
Operating Income Compound Annual Growth Rate in the last 5 years.
Net Income Compound Annual Growth Rate in the last 5 years.
Earnings Per Share Compound Annual Growth Rate in the last 5 years.
Cash Flow from Operating activities Compound Annual Growth Rate in the last 5 years.
...and much more!